Humacyte’s (HUMA) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Humacyte (NASDAQ:HUMA) in a research note released on Tuesday,Benzinga reports. D. Boral Capital currently has a $25.00 price target on the stock.

Several other equities analysts have also weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Humacyte in a research note on Monday, December 29th. Wall Street Zen downgraded Humacyte from a “hold” rating to a “sell” rating in a research report on Sunday, December 21st. Benchmark cut their price objective on Humacyte from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Wednesday, January 21st. HC Wainwright reaffirmed a “buy” rating and set a $3.00 target price on shares of Humacyte in a research note on Monday, December 1st. Finally, UBS Group reiterated a “buy” rating on shares of Humacyte in a research report on Monday, December 1st. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Humacyte presently has a consensus rating of “Moderate Buy” and an average price target of $8.14.

Humacyte Trading Down 18.9%

Shares of Humacyte stock opened at $0.86 on Tuesday. The firm has a 50-day simple moving average of $1.08 and a two-hundred day simple moving average of $1.31. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.90 and a current ratio of 1.62. Humacyte has a fifty-two week low of $0.81 and a fifty-two week high of $3.36. The company has a market cap of $161.05 million, a P/E ratio of -3.74 and a beta of 1.89.

Hedge Funds Weigh In On Humacyte

Several hedge funds and other institutional investors have recently modified their holdings of HUMA. Marshall Wace LLP boosted its holdings in shares of Humacyte by 5,308.2% during the 2nd quarter. Marshall Wace LLP now owns 2,639,194 shares of the company’s stock worth $5,516,000 after purchasing an additional 2,590,394 shares during the last quarter. CenterBook Partners LP increased its holdings in shares of Humacyte by 141.1% in the second quarter. CenterBook Partners LP now owns 3,430,255 shares of the company’s stock valued at $7,169,000 after purchasing an additional 2,007,743 shares during the last quarter. Millennium Management LLC increased its holdings in shares of Humacyte by 129.5% in the fourth quarter. Millennium Management LLC now owns 2,631,990 shares of the company’s stock valued at $2,528,000 after purchasing an additional 1,485,152 shares during the last quarter. UBS Group AG lifted its position in Humacyte by 48.8% during the fourth quarter. UBS Group AG now owns 2,978,610 shares of the company’s stock worth $2,862,000 after buying an additional 976,275 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in Humacyte by 33.4% during the second quarter. Geode Capital Management LLC now owns 2,948,508 shares of the company’s stock worth $6,163,000 after buying an additional 738,142 shares in the last quarter. 44.71% of the stock is owned by hedge funds and other institutional investors.

Humacyte Company Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.